Published: June 10, 2025Updated: June 11, 2025Written by: Beth DoughertyThere are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors. PARP inhibitors cause DNA to break. When broken strands and sketchy repairs … Read more
Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report, ranked as #3 in the nation…
Join Paolo Tarantino, MD, to learn about updates on treatment and research for metastatic breast cancer from the 2025 American Society of Clinical Oncology Conference.…
Immunopeptidomics is providing researchers with a powerful approach to discovering new ways to train a person’s immune system to fight cancer.
Boston residents rolled up their sleeps in anticipate of World Blood Donor Day on Saturday.
Published: May 19, 2025Updated: June 2, 2025Written by: Lukas Harnisch-WeidauerJyoti Bajpai, MD, DM, an oncologist practicing in the Apollo Hospital network in India, is well…
Published: May 7, 2025Written by: Dana-Farber Editorial TeamMedically Reviewed By: Ting Bao, MD, MSCold plunges, the act of immersing the body in cold water for…
When employees are satisfied in their work environment, the results speak for themselves. Newsweek and Plant-A Insights Group present America’s Greatest Workplaces 2025, recognizing companies…
In this episode, we discussed the management of systemic mastocytosis with Dr. Daniel DeAngelo from the Dana Farber Cancer Institute. Here are the key studies…
Antibody-drug conjugates are targeted agents that package cancer drugs for special delivery to tumor cells to eliminate them.
At ASCO 2025, Dana-Farber Cancer Institute researchers are leading four studies with compelling and potentially practice changing results in colorectal cancer and breast cancer. Investigators…
